OpenAI and the FDA are reportedly discussing AI for drug evaluations

Opina has met with officials of the US Food and Drug Administration (FDA) to discuss the use of the agency’s AI to increase the evaluation of the drug, Wired report Wednesday.

According to the report, the OpenAI and FDA discussed a project called CDRGPT, which appears to be an AI equipment in the Center for Drug Evaluation (CDE). The over-the-counter and prescription drugs in the Dose of CDE Elon Mask control the drugs that have been part of the discussion that has been part of the discussion.

It is not uncommon to take more than a decade to complete the drug development processes. The goal of the opening with the FDA was to accelerate a small part of its deadline for the wire. AI has long been identified as a potential accelerated that can be used across drug developmentTo make some infamously slow steps more efficient. It was said that there are unparalleled questions around how to control the incredibility of AI models.